Irritable bowel syndrome: Update on colonic neuromuscular dysfunction and treatment

Current Gastroenterology Reports

Volumn 8, Issue 4, 2006, Pages 273-281

  Chey, William D ^a   Cash, Brooks D ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ALVIMOPAN; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; CILANSETRON; CISAPRIDE; CITALOPRAM; CLONIDINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DESIPRAMINE; EZLOPITANT; FEDOTOZINE; FLUOXETINE; LUBIPROSTONE; MEBEVERINE; MELATONIN; MOSAPRIDE CITRATE; NEPADUTANT; NOLPITANTIUM; OPIATE ANTAGONIST; PAROXETINE; PRUCALOPRIDE; RENZAPRIDE; SAREDUTANT; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; UNINDEXED DRUG;

AUTONOMIC DYSFUNCTION; BACTERIAL OVERGROWTH; BLOATING; CELIAC DISEASE; CLINICAL TRIAL; COLON MOTILITY; COLON SECRETION; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; GENETIC EPIDEMIOLOGY; GENETIC PREDISPOSITION; HEART ARRHYTHMIA; HUMAN; INFLAMMATION; INTESTINAL DYSMOTILITY; INTESTINE DISTENSION; INTESTINE INNERVATION; IRRITABLE COLON; ISCHEMIC COLITIS; META ANALYSIS; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SCREENING TEST; SERODIAGNOSIS; SYSTEMATIC REVIEW; XEROSTOMIA;

COLON; HUMANS; IRRITABLE BOWEL SYNDROME; NEUROMUSCULAR AGENTS; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR JUNCTION DISEASES; TREATMENT OUTCOME;

EID: 33746865878     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-006-0047-z     Document Type: Review

References (51)

1. Talley NJ, Gabriel SE, Harmsen WS, et al.: Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995, 109:1736-1741.
2. Goodman C, Cronin K, Gemmen E, et al.: In The Burden of Gastrointestinal Diseases. Bethesda, MD: American Gastroenterological Association, 2001:2-65.
3. Drossman DA, Lesserman J, Nachman G, et al.: Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990, 113:828-833.
4. Camilleri M: Motor function in irritable bowel syndrome. Can J Gastroenterol 1999, 13(Suppl A):8A-11A.
5. Bouin M, Plourde V, Boivin M, et al.: Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002, 122:1771-1777.
6. Lawal A, Kern M, Sidhu H, et al.: Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 2006, 130:26-33.
7. Kalantar JS, Locke III GR, Zinsmeister AR, et al.: Familial aggregation of irritable bowel syndrome: a prospective study. Gut 2003, 52:1703-1707.
8. Levy RL, Jones KR, Whitehead WE, et al.: Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001, 121:799-804.
9. Saito YA, Petersen GM, Locke GR III, et al.: The genetics of irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005, 3:1057-1065.
10. Ohman L, Isaksson S, Lundgren A, et al.: A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005, 3:980-986.
11. Tornblom H, Lindberg G, Nyberg B, et al.: Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002, 123:1972-1979.
12. Spiller RC: Infection, immune function, and functional gut disorders. Clin Gastroenterol Hepatol 2004, 2:445-455.
13. Pimental M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506.
14. Spiegel BM, DeRosa VP, Gralnek IM, et al.: Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004, 126:1721-1732.
15. Camilleri M, Chey WY, Mayer EA, et al.: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001, 161:1733-1740.
16. Jones R, Holtmann G, Rodrigi L, et al.: Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999, 13:1419-1427.
17. Mayer EA, Berman S, Derbyshire SWG, et al.: The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002, 16:1357-1366.
18. Chey WD, Cash BD: Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert Opin Investig Drugs 2005, 14:1-9.
19. Novick J, Miner P, Krause R, et al.: A randomized, double-blind, placebo controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002, 16:877-888.
20. Kellow J, Lee OY, Chang FY, et al.: An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003, 52:671-676.
21. Bottoli I, Tougas G, Dunger-Baldauf C, et al.: Efficacy of tegaserod over 12 months in IBS-C patients: Do responders at month 3 still respond at month 12? Gastroenterology 2005, 128:A463-464.
22. Camilleri M, McKinzie S, Fox J, et al.: Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004, 2: 895-904.
23. Liu Z, Sakakibara R, Odaka T, et al.: Mosapride citrate, a novel S-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005, 20: 680-686.
24. Song GH, Leng, PH, Gwee, KA, et al.: Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomized, double-blind, placebo controlled trial. Gut 2005, 54:1402-1407.
25. Lu WX, Gwee KA, Moochhalla S, et al.: Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005, 22:927-934.
26. Jackson JL, O'Malley PG, Tomkins G, et al.: Treatment of functional bowel gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000, 108:65-72.
27. Drossman DA, Toner BB, Whitehead WE, et al.: Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003, 125:19-31.
28. Morgan V, Pickens D, Gautam S, et al.: Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut. 2005, 545:601-607.
29. Creed F, Fernandes L, Guthrie E, et al.: The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003, 124:303-317.
30. Tabas G, Beaves M, Wang J, et al.: Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004, 99:914-920.
31. Kuiken SD, Tytgat GNJ, Boeckxstaens GEE: The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003, 1:219-228.
32. Vahedi H, Merat S, Rashidioon A, et al.: The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double blind randomized-controlled study. Aliment Pharmacol Ther 2005, 22:381-385.
33. Masand PS, Gupta S, Scwartz TL, et al.: Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. Prim Care Companion J Clin Psychiatry 2005, 7:162-6.
34. Tack J, Broekaert D, Fischler B, et al.: A controlled cross-over study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006 Jan 9, [Epub ahead of print].
35. Fukudo S, Namura T, Hongo M: Impact of corticotrophin-releasing hormone on gastrointestinal motility and adrenocorticotrophic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998, 42:845-849.
36. Sagami Y, Shimada Y, Tayama J, et al.: Effect of a corticotrophin-releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004, 53:958-964.
37. Camilleri M: Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil 2005, 17:157-165.
38. Gonenne J, Camilleri M, Ferber I: Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005, 3:784-791.
39. Viscusi ER, Goldstein S, Witkowski T, et al.: Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc 2006, 20:64-70.
40. Delaney CP, Weese JL, Hyman NH, et al.: Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005, 48:1114-1125.
41. Delgado-Aros S, Chial HJ, Camilleri M, et al.: Effects of a κ opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol 2002, 284:G558-G566.
42. Delvaux M, Beck A, Jacob J, et al.: Effect of asimadoline, a κ opioid agonist, on pain induced by colonic distention in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20:237-246.
43. Lordal M, Navalesi G, Theodornsson E, et al.: A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 2001, 134:215-223.
44. Viramontes BE, Malcolm A, Camilleri M, et al.: Effects of α2-adrenergic agonist on gastrointestinal transit, colonic motility and sensation in humans. Am J Physiol 2001, 281:G1468-G1476.
45. Camilleri M, Kim D-Y, McKinzie S, et al.: A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003, 1:111-121.
46. Leventer S, Raudibaugh K, Frissora C, et al.: The safety and efficacy of dextofisopam in patients with diarrhea-predominant or alternating irritable bowel syndrome. Gastroenterology 2005, 128:A94.
47. Johanson JF, Gargano MA, Holland PC, et al.: Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. Gastroenterology 2003, 124:A48.
48. Johanson JF, Gargano MA, Holland PC, et al.: Multicenter open-label study of oral lubiprostone for the treatment of chronic constipation. Am J Gastroenterol 2005, 100:S331.
49. Eutamene H, Theodorou V, Tondereau V, et al.: Influence of guanylate cyclase C binding ligand MD-1100 on TNBS-induced visceral hypersensitivity in WT vs. KO guanylate cyclase C deficient mice. Gastroenterology 2006, 130(Suppl 2):A597.
50. Kurtz C, Fitch D, Busby RW, et al.: Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects. Gastroenterology 2006, 130 (Suppl 2):A26.
51. Cash BD, Chey WD: Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation. Aliment Pharmacol Ther. 2005, 22:1047-1060.